Related Experiment Video

Updated: Jun 20, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions

Alberto Ocaña1, Eitan Amir

  • 1Drug Development Program, Princess Margaret Hospital, Toronto, Canada M5G 2M9. alberto.ocana@uhn.on.ca

Cancer Treatment Reviews
|September 8, 2009
PubMed

Insights

New irreversible tyrosine kinase inhibitors show promise for HER2-positive breast cancer patients who do not respond to current therapies. These agents offer enhanced potency and prolonged inhibition, addressing resistance mechanisms.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2 overexpression drives certain breast cancers, making it a target for therapies like trastuzumab and lapatinib.
  • Some patients with HER2-positive breast cancer exhibit resistance to existing targeted therapies, necessitating novel treatment strategies.

Purpose of the Study:

  • To review the biologic rationale for developing irreversible tyrosine kinase inhibitors (TKIs) in breast cancer.
  • To discuss the current status and future directions of irreversible TKIs for HER2-positive breast cancer.

Main Methods:

  • Review of preclinical data on irreversible TKIs.
  • Analysis of clinical trial data for irreversible TKIs in breast cancer.

Main Results:

  • Irreversible TKIs demonstrate increased potency and prolonged HER2 inhibition in vitro.
  • Early clinical data suggest promising outcomes for irreversible TKIs in breast cancer treatment.

Conclusions:

  • Irreversible TKIs represent a promising therapeutic approach for overcoming resistance in HER2-positive breast cancer.
  • Further clinical development is warranted to establish the role of irreversible TKIs in breast cancer treatment regimens.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...